MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
FibroGen Operating Cycle 2011-2026 | FGEN
Annual Operating Cycle FibroGen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.28 K | 605 | 830 | 687 | 720 | 555 | 2.23 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.28 K | 555 | 1.13 K |
Quarterly Operating Cycle FibroGen
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.07 K | 3.79 K | - | -16.9 K | 19.2 K | 163 | - | 946 | 713 | 1.13 K | - | 998 | 681 | 844 | - | 770 | 793 | 598 | - | 770 | 89.1 | 132 | - | 35.3 | 2.97 | 133 | - | 200 | 132 | 103 | - | 28.3 | 26.6 | 29.3 | - | 31.7 | 10.7 | 41.7 | - | 72 | 11.7 | 80.8 | - | 89.8 | 13.7 | 34.3 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.2 K | -16.9 K | 278 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
408 | $ 9.13 | -0.76 % | $ 591 M |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.91 | 2.42 % | $ 6.69 M | China |
 |
Edesa Biotech
EDSA
|
97.1 | $ 15.52 | -2.39 % | $ 49.6 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
332 | $ 22.47 | 1.19 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Fortress Biotech
FBIO
|
325 | $ 2.24 | 0.9 % | $ 62.5 M | USA |
 |
Galapagos NV
GLPG
|
149 | $ 28.07 | 0.75 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.2 | 3.6 % | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
49.3 | $ 31.01 | -0.13 % | $ 1.78 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
ImmuCell Corporation
ICCC
|
232 | $ 8.44 | - | $ 76.2 M | USA |
 |
Immuron Limited
IMRN
|
1.46 K | $ 0.83 | 3.44 % | $ 6.55 M |  Australia |
 |
Incyte Corporation
INCY
|
145 | $ 98.87 | -0.23 % | $ 19.3 B | USA |
 |
InMed Pharmaceuticals
INM
|
313 | $ 0.71 | 1.28 % | $ 1.74 M |  Canada |
 |
INmune Bio
INMB
|
19.9 K | $ 1.35 | 1.5 % | $ 33.4 M | USA |
 |
Innoviva
INVA
|
24.6 | $ 23.13 | 0.35 % | $ 1.56 B | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Jaguar Health
JAGX
|
964 | $ 7.55 | -4.13 % | $ 17.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
213 | $ 26.67 | -0.02 % | $ 1.44 B | Britain |
 |
Kamada Ltd.
KMDA
|
269 | $ 8.15 | 0.49 % | $ 260 M |  Israel |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
77.8 | $ 223.98 | -0.39 % | $ 4.1 B | USA |
 |
Liquidia Corporation
LQDA
|
65.5 | $ 38.39 | 0.62 % | $ 3.3 B | USA |
 |
Aquestive Therapeutics
AQST
|
223 | $ 4.08 | 0.74 % | $ 436 M | USA |